Amgen Inc. (NASDAQ:AMGN) is Mcdonald Partners LLC’s 9th Largest Position

Mcdonald Partners LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,266 shares of the medical research company’s stock after acquiring an additional 464 shares during the period. Amgen makes up 1.4% of Mcdonald Partners LLC’s holdings, making the stock its 9th biggest holding. Mcdonald Partners LLC’s holdings in Amgen were worth $5,543,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of the company. Kentucky Retirement Systems Insurance Trust Fund increased its stake in Amgen by 67.9% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 26,706 shares of the medical research company’s stock worth $6,961,000 after buying an additional 10,797 shares during the period. Valley Wealth Managers Inc. grew its stake in shares of Amgen by 4.3% in the fourth quarter. Valley Wealth Managers Inc. now owns 80,604 shares of the medical research company’s stock worth $21,009,000 after acquiring an additional 3,306 shares in the last quarter. Bfsg LLC increased its position in shares of Amgen by 3.0% during the fourth quarter. Bfsg LLC now owns 13,647 shares of the medical research company’s stock worth $3,557,000 after acquiring an additional 399 shares during the period. BKM Wealth Management LLC raised its stake in shares of Amgen by 6.9% in the fourth quarter. BKM Wealth Management LLC now owns 7,016 shares of the medical research company’s stock valued at $1,829,000 after acquiring an additional 454 shares in the last quarter. Finally, Kestra Investment Management LLC boosted its holdings in Amgen by 4.3% in the fourth quarter. Kestra Investment Management LLC now owns 3,578 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 147 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock valued at $10,410,596 over the last three months. 0.69% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of analyst reports. Citigroup reduced their price target on Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Bank of America boosted their price target on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday, February 6th. Leerink Partners reduced their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective on shares of Amgen in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $314.09.

Amgen Trading Down 2.0 %

Shares of Amgen stock opened at $291.16 on Tuesday. The company’s fifty day moving average is $274.39 and its two-hundred day moving average is $301.10. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $156.51 billion, a P/E ratio of 38.56, a PEG ratio of 3.01 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts forecast that Amgen Inc. will post 20.59 earnings per share for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 119.21%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.